PE20070647A1 - Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1) - Google Patents

Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1)

Info

Publication number
PE20070647A1
PE20070647A1 PE2006001495A PE2006001495A PE20070647A1 PE 20070647 A1 PE20070647 A1 PE 20070647A1 PE 2006001495 A PE2006001495 A PE 2006001495A PE 2006001495 A PE2006001495 A PE 2006001495A PE 20070647 A1 PE20070647 A1 PE 20070647A1
Authority
PE
Peru
Prior art keywords
methyl
alkylazethyl
antagonists
fluoro
heterocicles
Prior art date
Application number
PE2006001495A
Other languages
English (en)
Spanish (es)
Inventor
Robert K Baker
Jeffrey J Hale
Kathleen M Rupprecht
Shouwu Miao
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20070647A1 publication Critical patent/PE20070647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2006001495A 2005-11-28 2006-11-23 Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1) PE20070647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
PE20070647A1 true PE20070647A1 (es) 2007-08-11

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001495A PE20070647A1 (es) 2005-11-28 2006-11-23 Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1)

Country Status (15)

Country Link
EP (1) EP1954692A1 (ru)
KR (1) KR20080073721A (ru)
AR (1) AR058199A1 (ru)
BR (1) BRPI0619018A2 (ru)
CR (1) CR10014A (ru)
DO (1) DOP2006000261A (ru)
EC (1) ECSP088477A (ru)
IL (1) IL191586A0 (ru)
MA (1) MA30086B1 (ru)
NO (1) NO20082919L (ru)
PE (1) PE20070647A1 (ru)
RU (1) RU2008126248A (ru)
SV (1) SV2009002917A (ru)
TW (1) TW200804317A (ru)
WO (1) WO2007062193A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009054923A2 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US7485732B2 (en) * 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
CN101426500A (zh) * 2005-05-02 2009-05-06 默克公司 治疗糖尿病和肥胖症的二肽基肽酶iv抑制剂和cb1受体拮抗剂的药物组合物

Also Published As

Publication number Publication date
RU2008126248A (ru) 2010-01-10
MA30086B1 (fr) 2008-12-01
BRPI0619018A2 (pt) 2016-11-29
EP1954692A1 (en) 2008-08-13
DOP2006000261A (es) 2007-07-15
ECSP088477A (es) 2008-06-30
CR10014A (es) 2008-07-29
TW200804317A (en) 2008-01-16
NO20082919L (no) 2008-08-27
IL191586A0 (en) 2008-12-29
WO2007062193A1 (en) 2007-05-31
KR20080073721A (ko) 2008-08-11
SV2009002917A (es) 2009-02-19
AR058199A1 (es) 2008-01-23

Similar Documents

Publication Publication Date Title
PE20070647A1 (es) Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1)
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20081229A1 (es) Antagonistas de receptor de orexina de diazepam sustituido
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20061093A1 (es) Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
PE20081472A1 (es) Compuestos de pirazolina
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a

Legal Events

Date Code Title Description
FD Application declared void or lapsed